Lumos Expands US Medicare Coverage for Respiratory Test; Shares Rise 4%

MT Newswires Live

2025/05/19

Lumos Diagnostics Holdings (ASX:LDX) has gained Medicare reimbursement for the company's point-of-care respiratory test, FebriDx, from US Medicare administrative contractor (MAC) WPS Health Solutions, at a rate of $41.38 per test, effective May 1, according to a Monday filing with the Australian bourse.

The company has now achieved coverage from five of seven MACs and said negotiations are ongoing with the remaining two.

Shares of the company rose 4% in recent Monday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2536547234"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536547234\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536547234?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-19 10:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536547234","market":"hk","top_or_hot":-1,"title":"Lumos Expands US Medicare Coverage for Respiratory Test; Shares Rise 4%","media":"MT Newswires Live","content":"<html><body><p> Lumos Diagnostics Holdings (ASX:LDX) has gained Medicare reimbursement for the company's point-of-care respiratory test, FebriDx, from US Medicare administrative contractor (MAC) WPS Health Solutions, at a rate of $41.38 per test, effective May 1, according to a Monday filing with the Australian bourse.</p><p>The company has now achieved coverage from five of seven MACs and said negotiations are ongoing with the remaining two.</p><p>Shares of the company rose 4% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lumos Expands US Medicare Coverage for Respiratory Test; Shares Rise 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLumos Expands US Medicare Coverage for Respiratory Test; Shares Rise 4%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-05-19 10:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Lumos Diagnostics Holdings (ASX:LDX) has gained Medicare reimbursement for the company's point-of-care respiratory test, FebriDx, from US Medicare administrative contractor (MAC) WPS Health Solutions, at a rate of $41.38 per test, effective May 1, according to a Monday filing with the Australian bourse.</p><p>The company has now achieved coverage from five of seven MACs and said negotiations are ongoing with the remaining two.</p><p>Shares of the company rose 4% in recent Monday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7126","symbol_name":"醫療保健用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2536547234","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536547234","pubTimestamp":1747620967,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lumos Diagnostics Holdings  has gained Medicare reimbursement for the company's point-of-care respiratory test, FebriDx, from US Medicare administrative contractor  WPS Health Solutions, at a rate of $41.38 per test, effective May 1, according to a Monday filing with the Australian bourse.The company has now achieved coverage from five of seven MACs and said negotiations are ongoing with the remaining two.Shares of the company rose 4% in recent Monday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7126":"医疗保健用品","MAC":"马塞里奇房产","LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L","BK4551":"寇图资本持仓","MAC.AU":"MAC Copper Ltd","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","BK7110":"铜"},"translate_title":"Lumos扩大美国医疗保险对呼吸测试的覆盖范围；股价上涨4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MAC":1,"LDX.AU":0.9,"MAC.AU":1},"content_text":"Lumos Diagnostics Holdings (ASX:LDX) has gained Medicare reimbursement for the company's point-of-care respiratory test, FebriDx, from US Medicare administrative contractor (MAC) WPS Health Solutions, at a rate of $41.38 per test, effective May 1, according to a Monday filing with the Australian bourse.The company has now achieved coverage from five of seven MACs and said negotiations are ongoing with the remaining two.Shares of the company rose 4% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}